Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy

Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy

<p>Abstract</p> <p>Background</p> <p>Oxidative stress could play a role in pathogenesis of hepatitis C virus (HCV) infection. The aim of our study is to determine oxidant/antioxidant status of patients with chronic hepatitis C (CHC), and the effect of pegylated interfer...

Full description

Bibliographic Details
Main Authors:	Aytaç Çetinkaya, Polat Eyigun, Ahmet Aydın, Ali Acar, Levent Görenek, Ayşe Eken, Ahmet Sayal
Format:	Article
Language:	English
Published:	BMC 2006-06-01
Series:	Journal of Translational Medicine
Online Access:	http://www.translational-medicine.com/content/4/1/25

Similar Items

Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
by: T Kanda, et al.
Published: (2011-03-01)

The Association of Liver Fibrosis with Effectiveness of Pegylated Interferon Alfa-2b Plus Ribavirin for Chronic Hepatitis C
by: Yi-chih Chen, et al.
Published: (2007)

Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents
by: Jaber Al Ali, et al.
Published: (2010-04-01)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
by: Gonçales Neiva SL, et al.
Published: (2010-07-01)

Treatment of Ribavirin/Pegylated Interferon Alfa - Induced Anemiawith Erythropoietin in Patients with Chronic Hepatitis C
by: Li-Shuan Chen, et al.
Published: (2006)

Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
by: Rahmet Güner, et al.
Published: (2013-06-01)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
by: R. Rodríguez-Lojo, et al.
Published: (2010-01-01)

Autoantibodies profile in patients with chronic hepatitis C and the influence of Interferon-alfa plus Ribavirin
by: Janaina LeitÃo Vilar
Published: (2006)

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b
by: Jovanović-Ćupić Snežana, et al.
Published: (2014-01-01)

Ribavirin plus interferon alfa in the treatment of chronic hepatitis C infection
by: Wen Hwang Chen, et al.
Published: (2000)

Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
by: Konstantinos D. Pantazis, et al.
Published: (2008-01-01)

Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin
by: Kuo-Chih Tseng, et al.
Published: (2017-05-01)

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
by: Picardi Antonio, et al.
Published: (2010-02-01)

Prognostic Effect of Human Leukocyte Antigen Class I and II Alleles on Chronic Hepatitis C Patients Treated by Pegylated Interferon-Alfa plus Ribavirin in Taiwan
by: Kuo-Chih Tseng, et al.
Published: (2009)

Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis
by: Ming-Chao Tsai, et al.
Published: (2009-09-01)

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
by: J Shepherd, et al.
Published: (2007-03-01)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
by: Juan Macías, et al.
Published: (2015-01-01)

Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients
by: Dumitru Irina Magdalena, et al.
Published: (2017-02-01)

Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin
by: Chia-Min Wu, et al.
Published: (2021-03-01)

Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with Pegylated interferon alfa-2a and ribavirin
by: Fabri Milotka, et al.
Published: (2013-01-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
by: Saleem Sana, et al.
Published: (2011-05-01)

The analysis of different course of treatment with pegylated interferon plus ribavirin to genotype 1 hepatitis C virus
by: Chiu-Chun, et al.
Published: (2009)

The Study on Adverse Events Induced byPegylated Interferon Alpha plus Ribavirin in Chronic Hepatitis C
by: Shu-Hui Kuo, et al.
Published: (2007)

Clinical characteristics and virological responses to pegylated interferon plus ribavirin combination therapy in the hepatitis B and C virus coinfected patients
by: J. You, et al.
Published: (2014-04-01)

Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.
by: Tetsuro Takayama, et al.
Published: (2011-01-01)

Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
by: Geng-lin Zhang, et al.
Published: (2017-01-01)

The treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection
by: Ching-I Huang, et al.
Published: (2014)

The Number and Function of Dendritic Cells in Patients with Hepatitis C Virus Genotype 1 Infection Treated with Pegylated Interferon plus Ribavirin
by: Cheng-Chao Liang, et al.
Published: (2009)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
by: Izabella Liguori Corsino VABO, et al.

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
by: Roberto J Carvalho-Filho, et al.
Published: (2010-03-01)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
by: Amit Chopra, et al.
Published: (2015-01-01)

Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
by: Yi-Hao Yen, et al.
Published: (2015-07-01)

Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
by: Yi Hao Yen, et al.
Published: (2013)

Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection
by: Ta-Ya Lin, et al.
Published: (2017-06-01)

The Effect of Self-management for C-type Hepatitis Patients with Pegylated Interferon-α plus Ribavirin Treatments applying Animated Health Education CD
by: LIU, YI-CHEN, et al.
Published: (2017)

Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China
by: Wangxia Tong, et al.
Published: (2016-01-01)

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
by: Ta-Wei Liu, et al.
Published: (2018-01-01)

Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin
by: Fernando José de Novelli, et al.
Published: (2014-06-01)